Predicine and Flagship Biosciences are excited to announce a strategic venture. The synergistic combination of Predicine’s GeneRADAR molecular insights platform with Flagship’s artificial intelligence-enabled cTA® digital pathology platform provides complimentary and comprehensive biomarker profiling to empower clinical trials in the immuno-oncology (IO) space. IO therapies have changed the way we think about patient selection for...